EUVIMEDEUVIMED entdecken
Crossref

The Prognostic Significance of Ki-67 Expression in Breast Cancers Developing Malignant Effusions

Ilias P Nikas, So Hyeon Yang, Sojung Lim, Hyebin Lee, Han Suk Ryu

Acta Cytologica · 2025

DOI: 10.1159/000546180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Cytologica, 2025. Verfasst von Ilias P Nikas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Cyprus, Nicosia, Cyprus, ilias.nikas@gmail.com. Hauptthemen laut MEDLINE: Ki-67 Antigen, Biomarkers, Tumor, Pleural Effusion, Malignant, Breast Neoplasms. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of this study was to investigate the prognostic significance of Ki-67 in breast cancer patients developing malignant effusions.

Methods

In this retrospective study, 76 breast cancer patients developing a malignant effusion were enrolled. The Ki-67 immunohistochemistry (IHC) findings from both initial tissue and paired metastatic effusion samples of these patients were grouped into the following three categories: ≤5, 6–29, and ≥30%.

Results

Triple-negative breast cancer (TNBC) showed higher Ki-67 levels at both initial diagnosis (p < 0.001) and malignant effusion samples (p = 0.015), compared to the non-TNBC phenotypes at the same tumor evolution phases, respectively. A Ki-67 ≥30% at initial diagnosis was associated with a shorter overall survival (p = 0.031; long-rank test), in addition to an earlier development of a malignant effusion (p < 0.001; long-rank test). A Ki-67 ≤5% at malignant effusion cell block samples was associated with a longer post-effusion survival (p = 0.015; long-rank test). Lastly, a Ki-67 index ≤5% at the effusion samples showed a significantly lower risk of mortality following the development of malignant effusions (HR: 0.355 [0.150–0.842; p = 0.019]), after being adjusted for the intrinsic subtype covariate (TNBC vs. non-TNBC).

Conclusion

Estimating the Ki-67 IHC expression in malignant effusion cytology samples may have a prognostic significance, when evaluating patients with metastatic breast cancer. However, larger scale prospective studies would be necessary to provide more evidence on this topic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ki-67 AntigenBiomarkers, TumorPleural Effusion, MalignantBreast NeoplasmsTriple Negative Breast NeoplasmsHumansFemaleRetrospective StudiesMiddle AgedPrognosisAgedAdultImmunohistochemistryAged, 80 and overPredictive Value of Tests

Stichwörter der Autor:innen

BiomarkerBreast cancerCytopathologyImmunohistochemistryMetastasisPrognosis

Substanzen

Ki-67 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Medical School, University of Cyprus, Nicosia, Cyprus, ilias.nikas@gmail.com.
  • Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Forensic Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Radiation Oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.

Zitieren

APA

Nikas, I. P., Yang, S. H., Lim, S., Lee, H., & Ryu, H. S. (2025). The Prognostic Significance of Ki-67 Expression in Breast Cancers Developing Malignant Effusions. Acta Cytologica. https://doi.org/10.1159/000546180

Vancouver

Nikas IP, Yang SH, Lim S, Lee H, Ryu HS. The Prognostic Significance of Ki-67 Expression in Breast Cancers Developing Malignant Effusions. Acta Cytologica. 2025. doi:10.1159/000546180

BibTeX
@article{Nikas2025,
  author = {Nikas, Ilias P and Yang, So Hyeon and Lim, Sojung and Lee, Hyebin and Ryu, Han Suk},
  title = {The Prognostic Significance of Ki-67 Expression in Breast Cancers Developing Malignant Effusions},
  journal = {Acta Cytologica},
  year = {2025},
  doi = {10.1159/000546180}
}
Kostenlos starten →